InvestorsHub Logo
Followers 139
Posts 23241
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Saturday, 08/18/2018 10:40:31 PM

Saturday, August 18, 2018 10:40:31 PM

Post# of 403091
Let's compare Prurisol to Celgene's Otezla

Celgene had a small Phase 2 trial for Otezla (apremilast, CC-10004) there were only 30 subjects in the treatment phase.


...the proportion of subjects achieving PASI 75 was 30%....




...9 subjects achieved PASI 75....




...several subjects (4) dropped out early (on or prior to week 4) due to intolerability (gastrointestinal effects) or withdrawn consent....




That is very similar to the proportion of subjects achieving
PASI 75 in the larger Otezla Phase 4 trials.

https://media.celgene.com/content/uploads/CC-10004-PSOR-004-Synopsis-Redacted.pdf

Now compare those results to the Prurisol Phase 2 trial results.



https://static1.squarespace.com/static/5715352e20c647639137f992/t/583ddc8303596e5fc7e8bf06/1480449160455/Cellceutix_Corporate_Slide+Deck_DERMATOLOGY_November+2016+Website+Vers.pdf

Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News